JP2018168170A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018168170A5 JP2018168170A5 JP2018111869A JP2018111869A JP2018168170A5 JP 2018168170 A5 JP2018168170 A5 JP 2018168170A5 JP 2018111869 A JP2018111869 A JP 2018111869A JP 2018111869 A JP2018111869 A JP 2018111869A JP 2018168170 A5 JP2018168170 A5 JP 2018168170A5
- Authority
- JP
- Japan
- Prior art keywords
- acid
- composition
- alcohol
- compound
- cis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 56
- 150000001875 compounds Chemical class 0.000 claims 33
- 150000002191 fatty alcohols Chemical class 0.000 claims 23
- 125000003700 epoxy group Chemical group 0.000 claims 19
- 102000001708 Protein Isoforms Human genes 0.000 claims 16
- 108010029485 Protein Isoforms Proteins 0.000 claims 16
- 102000003923 Protein Kinase C Human genes 0.000 claims 16
- 108090000315 Protein Kinase C Proteins 0.000 claims 16
- 235000014113 dietary fatty acids Nutrition 0.000 claims 13
- 229930195729 fatty acid Natural products 0.000 claims 13
- 239000000194 fatty acid Substances 0.000 claims 13
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 claims 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 12
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims 12
- 229950011148 cyclopropane Drugs 0.000 claims 10
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 10
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 claims 8
- 101150065749 Churc1 gene Proteins 0.000 claims 8
- 102100038239 Protein Churchill Human genes 0.000 claims 8
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims 8
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 8
- -1 fatty acid esters Chemical class 0.000 claims 7
- 150000004665 fatty acids Chemical class 0.000 claims 7
- YUFFSWGQGVEMMI-JLNKQSITSA-N (7Z,10Z,13Z,16Z,19Z)-docosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCCC(O)=O YUFFSWGQGVEMMI-JLNKQSITSA-N 0.000 claims 6
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 claims 6
- 235000021294 Docosapentaenoic acid Nutrition 0.000 claims 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 6
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims 6
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims 6
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims 6
- 229940090949 docosahexaenoic acid Drugs 0.000 claims 6
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims 6
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims 6
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims 6
- 230000004770 neurodegeneration Effects 0.000 claims 6
- 229940055577 oleyl alcohol Drugs 0.000 claims 6
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 claims 6
- TWSWSIQAPQLDBP-CGRWFSSPSA-N (7e,10e,13e,16e)-docosa-7,10,13,16-tetraenoic acid Chemical compound CCCCC\C=C\C\C=C\C\C=C\C\C=C\CCCCCC(O)=O TWSWSIQAPQLDBP-CGRWFSSPSA-N 0.000 claims 4
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 claims 4
- IKYKEVDKGZYRMQ-PDBXOOCHSA-N (9Z,12Z,15Z)-octadecatrien-1-ol Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCCO IKYKEVDKGZYRMQ-PDBXOOCHSA-N 0.000 claims 4
- 235000021292 Docosatetraenoic acid Nutrition 0.000 claims 4
- 230000003213 activating effect Effects 0.000 claims 4
- TWSWSIQAPQLDBP-UHFFFAOYSA-N adrenic acid Natural products CCCCCC=CCC=CCC=CCC=CCCCCCC(O)=O TWSWSIQAPQLDBP-UHFFFAOYSA-N 0.000 claims 4
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims 4
- 235000021342 arachidonic acid Nutrition 0.000 claims 4
- 229940114079 arachidonic acid Drugs 0.000 claims 4
- 229960004488 linolenic acid Drugs 0.000 claims 4
- QYDYPVFESGNLHU-KHPPLWFESA-N methyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC QYDYPVFESGNLHU-KHPPLWFESA-N 0.000 claims 4
- 150000002148 esters Chemical class 0.000 claims 3
- CCPPLLJZDQAOHD-BEBBCNLGSA-N (-)-vernolic acid Chemical compound CCCCC[C@@H]1O[C@@H]1C\C=C/CCCCCCCC(O)=O CCPPLLJZDQAOHD-BEBBCNLGSA-N 0.000 claims 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 claims 2
- DPUOLQHDNGRHBS-UHFFFAOYSA-N Brassidinsaeure Natural products CCCCCCCCC=CCCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-UHFFFAOYSA-N 0.000 claims 2
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 claims 2
- URXZXNYJPAJJOQ-UHFFFAOYSA-N Erucic acid Natural products CCCCCCC=CCCCCCCCCCCCC(O)=O URXZXNYJPAJJOQ-UHFFFAOYSA-N 0.000 claims 2
- 208000019022 Mood disease Diseases 0.000 claims 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- YHVNLORIIDPMPQ-RRABGKBLSA-N cyclopropane;(e)-octadec-9-enoic acid Chemical compound C1CC1.CCCCCCCC\C=C\CCCCCCCC(O)=O YHVNLORIIDPMPQ-RRABGKBLSA-N 0.000 claims 2
- VCDLWFYODNTQOT-UHFFFAOYSA-N docosahexaenoic acid methyl ester Natural products CCC=CCC=CCC=CCC=CCC=CCC=CCCC(=O)OC VCDLWFYODNTQOT-UHFFFAOYSA-N 0.000 claims 2
- IQLUYYHUNSSHIY-HZUMYPAESA-N eicosatetraenoic acid Chemical compound CCCCCCCCCCC\C=C\C=C\C=C\C=C\C(O)=O IQLUYYHUNSSHIY-HZUMYPAESA-N 0.000 claims 2
- QYDYPVFESGNLHU-UHFFFAOYSA-N elaidic acid methyl ester Natural products CCCCCCCCC=CCCCCCCCC(=O)OC QYDYPVFESGNLHU-UHFFFAOYSA-N 0.000 claims 2
- DPUOLQHDNGRHBS-KTKRTIGZSA-N erucic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-KTKRTIGZSA-N 0.000 claims 2
- 229940098330 gamma linoleic acid Drugs 0.000 claims 2
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 claims 2
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 claims 2
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 claims 2
- LUYYTKKXYNRVHQ-TYYHYDAASA-N methyl (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoate Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(=O)OC LUYYTKKXYNRVHQ-TYYHYDAASA-N 0.000 claims 2
- JTSVQVYMBXVLFI-IPASSIEDSA-N methyl (z)-11-[(2r,3s)-3-pentyloxiran-2-yl]undec-9-enoate Chemical compound CCCCC[C@@H]1O[C@@H]1C\C=C/CCCCCCCC(=O)OC JTSVQVYMBXVLFI-IPASSIEDSA-N 0.000 claims 2
- 150000004702 methyl esters Chemical class 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 claims 2
- CCPPLLJZDQAOHD-UHFFFAOYSA-N vernolic acid Natural products CCCCCC1OC1CC=CCCCCCCCC(O)=O CCPPLLJZDQAOHD-UHFFFAOYSA-N 0.000 claims 2
- DVWSXZIHSUZZKJ-UHFFFAOYSA-N 18:3n-3 Natural products CCC=CCC=CCC=CCCCCCCCC(=O)OC DVWSXZIHSUZZKJ-UHFFFAOYSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- DVWSXZIHSUZZKJ-YSTUJMKBSA-N methyl linolenate Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(=O)OC DVWSXZIHSUZZKJ-YSTUJMKBSA-N 0.000 claims 1
- 235000021281 monounsaturated fatty acids Nutrition 0.000 claims 1
- 239000001294 propane Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8417208P | 2008-07-28 | 2008-07-28 | |
| US61/084,172 | 2008-07-28 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016051212A Division JP6449186B2 (ja) | 2008-07-28 | 2016-03-15 | 神経変性疾患の治療のためのｐｋｃ活性化化合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018168170A JP2018168170A (ja) | 2018-11-01 |
| JP2018168170A5 true JP2018168170A5 (enExample) | 2019-03-14 |
Family
ID=41136734
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011521235A Expired - Fee Related JP5653917B2 (ja) | 2008-07-28 | 2009-07-28 | 神経変性疾患の治療のためのｐｋｃ活性化化合物 |
| JP2014182597A Pending JP2015042643A (ja) | 2008-07-28 | 2014-09-08 | 神経変性疾患の治療のためのｐｋｃ活性化化合物 |
| JP2016051212A Expired - Fee Related JP6449186B2 (ja) | 2008-07-28 | 2016-03-15 | 神経変性疾患の治療のためのｐｋｃ活性化化合物 |
| JP2018111869A Pending JP2018168170A (ja) | 2008-07-28 | 2018-06-12 | 神経変性疾患の治療のためのｐｋｃ活性化化合物 |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011521235A Expired - Fee Related JP5653917B2 (ja) | 2008-07-28 | 2009-07-28 | 神経変性疾患の治療のためのｐｋｃ活性化化合物 |
| JP2014182597A Pending JP2015042643A (ja) | 2008-07-28 | 2014-09-08 | 神経変性疾患の治療のためのｐｋｃ活性化化合物 |
| JP2016051212A Expired - Fee Related JP6449186B2 (ja) | 2008-07-28 | 2016-03-15 | 神経変性疾患の治療のためのｐｋｃ活性化化合物 |
Country Status (6)
| Country | Link |
|---|---|
| US (7) | US8163800B2 (enExample) |
| EP (3) | EP3586839A1 (enExample) |
| JP (4) | JP5653917B2 (enExample) |
| CA (2) | CA2941035A1 (enExample) |
| ES (1) | ES2683021T3 (enExample) |
| WO (1) | WO2010014585A1 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090030055A1 (en) * | 2002-07-02 | 2009-01-29 | Thomas Nelson | PKC activation as a means for enhancing sAPPALPHA secretion and improving cognition using bryostatin type compounds |
| ES2683021T3 (es) | 2008-07-28 | 2018-09-24 | Blanchette Rockefeller Neurosciences Institute | Compuestos activadores de la PKC para el tratamiento de enfermedades neurodegenerativas |
| EP3536317A1 (en) | 2009-10-30 | 2019-09-11 | Retrotope, Inc. | Alleviating oxidative stress disorders with pufa derivatives |
| JP5902103B2 (ja) * | 2010-02-22 | 2016-04-13 | ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート | プロテインキナーゼｃイプシロン（ｐｋｃ−イプシロン）タンパク質レベルの、アルツハイマー病に特異的な変化 |
| WO2012006525A2 (en) | 2010-07-08 | 2012-01-12 | Alkon Daniel L | Pkc activators and anticoagulant in regimen for treating stroke |
| US9597312B2 (en) | 2010-08-19 | 2017-03-21 | Cognitive Research Enterprises, Inc. | Treatment of cognitive disorders associated with abnormal dendritic spines using PKC activators |
| AU2012249920B2 (en) | 2011-04-26 | 2017-06-15 | Biojiva Llc | Disorders implicating PUFA oxidation |
| AU2012249918B2 (en) * | 2011-04-26 | 2017-06-15 | Biojiva Llc | Impaired energy processing disorders and mitochondrial deficiency |
| US10058522B2 (en) | 2011-04-26 | 2018-08-28 | Retrotope, Inc. | Oxidative retinal diseases |
| CA2834274C (en) | 2011-04-26 | 2021-08-03 | Retrotope, Inc. | Neurodegenerative disorders and muscle diseases implicating pufas |
| WO2013052922A1 (en) | 2011-10-05 | 2013-04-11 | Blanchette Rockefeller Neurosciences Institute | Stimulus-elicited genomic profile markers of a neurodegenerative condition |
| US10821079B2 (en) * | 2011-11-13 | 2020-11-03 | Cognitive Research Enterprises, Inc. | PKC activators and combinations thereof |
| WO2013071281A1 (en) | 2011-11-13 | 2013-05-16 | Blanchette Rockefeller Neurosciences Institute | Esters of dcpla and methods of treatment using the same |
| EP2957285B1 (en) * | 2013-02-15 | 2018-01-10 | Nishizaki Bioinformation Research Institute | Phospholipid compound containing unsaturated fatty acid derivative having cyclopropane ring |
| CA2906164A1 (en) * | 2013-03-15 | 2014-09-18 | Daniel L. Alkon | Methods for identifying neuroprotective pkc activators |
| PT3057934T (pt) | 2013-10-18 | 2019-06-28 | Blanchette Rockefeller Neurosciences Inst | Ésteres halogenados de ácidos gordos insaturados ciclopropanados para uso no tratamento de doenças neurodegenerativas |
| WO2015160851A1 (en) | 2014-04-18 | 2015-10-22 | Neurotrope Bioscience | Methods and compositions for treatment of lipid storage disorders |
| US9413754B2 (en) | 2014-12-23 | 2016-08-09 | Airwatch Llc | Authenticator device facilitating file security |
| CA2985625A1 (en) | 2015-05-11 | 2016-11-17 | Alkon, Daniel L. | Treatment of neurodegenerative conditions using pkc activators after determining the presence of the apoe4 allele |
| US20180256537A1 (en) | 2015-09-23 | 2018-09-13 | Tapan K. Khan | Methods for survival and rejuvenation of dermal fibroblasts using pkc activators |
| US20180311209A1 (en) | 2015-10-08 | 2018-11-01 | Cognitive Research Enterprises, Inc. | Dosing regimens of pkc activators |
| EP3380452B1 (en) | 2015-11-23 | 2021-03-24 | Retrotope, Inc. | Site-specific isotopic labeling of 1, 4-diene systems |
| JP6912072B2 (ja) * | 2016-12-14 | 2021-07-28 | 国立大学法人山口大学 | 前頭側頭型認知症の予防又は治療用医薬 |
| WO2018187647A1 (en) | 2017-04-06 | 2018-10-11 | Neurotrope Bioscience, Inc. | Methods and compositions for treatment of neurological diseases, disorders, or conditions |
| EP3964210A1 (en) * | 2018-05-18 | 2022-03-09 | Neurotrope Bioscience, Inc. | Methods and compositions for treatment of alzheimer's disease |
| US20220023255A1 (en) * | 2018-12-07 | 2022-01-27 | The Johns Hopkins University | Methods, compositions and kits for treating multiple sclerosis and other disorders |
| CN116438187A (zh) | 2020-02-21 | 2023-07-14 | 拜奥吉瓦有限责任公司 | 多不饱和脂肪酸及其衍生物的同位素修饰方法 |
| US20220133687A1 (en) * | 2020-11-02 | 2022-05-05 | Synaptogenix, Inc. | Methods of treating and preventing neurodegenerative diseases with hgf activating compounds |
| US12109194B2 (en) | 2021-02-05 | 2024-10-08 | Biojiva Llc | Synergistic combination therapy for treating ALS |
| US20240165075A1 (en) * | 2021-02-08 | 2024-05-23 | Synaptogenix, Inc. | Treatment of optic nerve inflammation using pkc activators |
| EP4288047A4 (en) * | 2021-02-08 | 2024-12-11 | Synaptogenix, Inc. | Treatment of multiple sclerosis using pkc activators |
| US20250345400A1 (en) * | 2022-05-18 | 2025-11-13 | Virginia Commonwealth University | Methods for treatment of cognitive impairment in cirrhosis patients |
| WO2025056602A1 (en) | 2023-09-11 | 2025-03-20 | Elastin Biosciences Ltd. | Pharmaceutical compositions and use thereof in treatment of conditions and diseases related to elastin deficiency and/or aging |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6080784A (en) | 1986-06-11 | 2000-06-27 | Procyon Pharmaceuticals, Inc. | Protein kinase C modulators N |
| US5242932A (en) | 1991-12-17 | 1993-09-07 | The Rockefeller University | Treatment of amyloidosis associated with alzheimer disease |
| US5385915A (en) | 1990-05-16 | 1995-01-31 | The Rockefeller University | Treatment of amyloidosis associated with Alzheimer disease using modulators of protein phosphorylation |
| ATE386115T1 (de) | 1991-12-06 | 2008-03-15 | Max Planck Gesellschaft | Verwendung von proteinkinasen zur diagnose und behandlung der alzheimer krankheit |
| US5766846A (en) | 1992-07-10 | 1998-06-16 | Athena Neurosciences | Methods of screening for compounds which inhibit soluble β-amyloid peptide production |
| JPH06279311A (ja) | 1993-03-26 | 1994-10-04 | Sagami Chem Res Center | プロテインキナーゼｃアイソザイムの活性化剤 |
| US5976816A (en) | 1993-05-03 | 1999-11-02 | The United States Of America As Represented By The Department Of Health And Human Services | Cell tests for alzheimer's disease |
| US20030108956A1 (en) | 1993-05-03 | 2003-06-12 | Alkon Daniel L. | Cell tests for Alzheimer's disease |
| US6107050A (en) | 1993-05-03 | 2000-08-22 | The United States Of America As Represented By The Department Of Health And Human Services | Diagnostic test for alzheimers disease |
| US7625697B2 (en) | 1994-06-17 | 2009-12-01 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for constructing subarrays and subarrays made thereby |
| US5872101A (en) | 1995-01-06 | 1999-02-16 | Sibia Neurosciences, Inc. | Methods of treating neurodegenerative disorders using protease inhibitors |
| US6303567B1 (en) | 1995-03-14 | 2001-10-16 | Praecis Pharmaceuticals, Inc . | Modulators of β-amyloid peptide aggregation comprising D-amino acids |
| CA2172771A1 (en) | 1995-03-28 | 1996-09-29 | Akiyoshi Tani | Method for assaying map kinase |
| US6277826B1 (en) | 1996-08-27 | 2001-08-21 | Praecis Pharmaceuticals, Inc. | Modulators of β-amyloid peptide aggregation comprising D-amino acids |
| US6077686A (en) | 1996-02-29 | 2000-06-20 | Mount Sinai Hospital Corporation | Shc proteins |
| JPH1090263A (ja) | 1996-07-25 | 1998-04-10 | Mclean Hospital Corp:The | アルツハイマー病の診断のためのｅｒｋ−１およびｅｒｋ−２の利用 |
| JP2002526775A (ja) | 1998-10-01 | 2002-08-20 | テイテイエブスキ，アレクセイ・ウラデイミロビチ | ＧＤＮＦについての新規Ｒｅｔ非依存性シグナリング経路 |
| AU5150300A (en) | 1999-05-19 | 2000-12-05 | Mitokor | Differential gene expression in specific regions of the brain in neurodegenerative diseases |
| WO2001027624A2 (en) | 1999-10-08 | 2001-04-19 | Superarray, Inc. | Compositions and methods for detecting protein modification and enzymatic activity |
| US20030165481A1 (en) | 2000-02-24 | 2003-09-04 | Hersh Louis B. | Amyloid peptide inactivating enzyme to treat Alzheimer's disease |
| JP2003527604A (ja) | 2000-03-10 | 2003-09-16 | ワシントン・ユニバーシティ | 個々の細胞の標識方法 |
| AU2001252958A1 (en) | 2000-03-23 | 2001-10-03 | Elan Pharmaceuticals, Inc. | Compounds and methods to treat alzheimer's disease |
| US6495540B2 (en) | 2000-03-28 | 2002-12-17 | Bristol - Myers Squibb Pharma Company | Lactams as inhibitors of A-β protein production |
| MXPA02009729A (es) | 2000-04-03 | 2003-03-27 | Bristol Myers Squibb Pharma Co | Lactamas ciclicas como inhibidores de la produccion de la proteina a-beta. |
| US6632812B2 (en) | 2000-04-11 | 2003-10-14 | Dupont Pharmaceuticals Company | Substituted lactams as inhibitors of Aβ protein production |
| DE60116313T2 (de) | 2000-06-30 | 2006-08-31 | Elan Pharmaceuticals, Inc., San Francisco | Verbindungen zur behandlung der alzheimerischen krankheit |
| CA2417744A1 (en) | 2000-07-31 | 2002-02-07 | The Regents Of The University Of California | Model for alzheimer's disease and other neurodegenerative diseases |
| NZ538100A (en) | 2000-12-13 | 2006-07-28 | Arqule Inc | Heterocyclic sulfonamide inhibitors of beta amyloid production |
| AUPR215700A0 (en) * | 2000-12-19 | 2001-01-25 | Fujisawa Pharmaceutical Co., Ltd. | Carboxylic acid compound having cyclopropane ring |
| US7374911B2 (en) | 2000-12-21 | 2008-05-20 | Labow Mark A | Interleukin-1 related gene and protein |
| JP2005503112A (ja) | 2001-02-06 | 2005-02-03 | インサイト・ゲノミックス・インコーポレイテッド | 脂質結合分子 |
| JP4024554B2 (ja) | 2001-02-27 | 2007-12-19 | 松下電器産業株式会社 | 燃料電池発電システム |
| KR100960256B1 (ko) | 2001-02-27 | 2010-06-01 | 블랜체트 록펠러 뉴로사이언시즈 인스티튜트 | 유사분열 촉진인자-활성화 단백질 키나제 인산화에 근거한 알쯔하이머병 진단 |
| US6874208B2 (en) | 2001-03-14 | 2005-04-05 | Autoliv Asp, Inc. | Anchoring attachment apparatus |
| WO2003002122A1 (en) | 2001-06-27 | 2003-01-09 | Elan Pharmaceuticals, Inc. | Beta-hydroxyamine derivatives useful in treatment of alzheimer's disease |
| US20040014678A1 (en) | 2001-08-08 | 2004-01-22 | Antonella Favit | Prevention of beta-amyloid neurotoxicity by blockade of the ubiquitin-proteasome proteolytoc pathway |
| WO2004083241A2 (en) | 2003-03-19 | 2004-09-30 | Takeda Pharmaceutical Company Limited | Btc-interacting proteins and use thereof |
| WO2006050475A2 (en) | 2004-11-03 | 2006-05-11 | Brigham And Women's Hospital, Inc. | Identification of dysregulated genes in patients with neurological diseases |
| EP1812588A4 (en) | 2004-11-15 | 2009-06-10 | Brni Neurosciences Inst | ANOMALIES OF PHOSPHATASE 2A (PP2A) FOR THE DIAGNOSIS AND TREATMENT OF ALZHEIMER'S DISEASE |
| WO2007019080A2 (en) | 2005-08-03 | 2007-02-15 | Merck & Co., Inc. | Tricyclic beta-secretase inhibitors for the treatment of alzheimer's disease |
| US7595167B2 (en) | 2005-10-11 | 2009-09-29 | Blanchette Rockefeller Neurosciences Institute | Alzheimer's disease-specific alterations of the Erk1/Erk2 phosphorylation ratio |
| WO2007047029A2 (en) | 2005-10-11 | 2007-04-26 | Blanchette Rockefeller Neurosciences Institute | Alzheimer's disease-specific alterations of the erk1/erk2 phosphorylation ratio as alzheimer's disease-specific molecular biomarkers (adsmb) |
| WO2007043998A1 (en) | 2005-10-11 | 2007-04-19 | Blanchette Rockefeller Neurosciences Institute | Alzheimer’s disease-specific alterations of the erk1/erk2 phosphorylation ratio |
| US20090029873A1 (en) | 2005-10-11 | 2009-01-29 | Blanchette Rockefeller Neurosciences Institute | Alzheimer's Disease-Specific Alterations of the Erk1/Erk2 Phosphorylation Ratio-Alzheimer's Disease-Specific Molecular Biomarkers (Adsmb) |
| WO2007044094A1 (en) | 2005-10-11 | 2007-04-19 | Blanchette Rockefeller Neurosciences Institute | Alzheimer's disease-specific alterations of the erk1/erk2 phosphorylation ratio as alzheimer's disease-specific molecular biomarkers (adsmb) |
| KR20090024808A (ko) | 2006-06-21 | 2009-03-09 | 렉시코어 메디컬 테크놀로지 엘엘씨 | 치매 및 치매성 장애의 평가 |
| JP2008143819A (ja) * | 2006-12-08 | 2008-06-26 | Tomoyuki Nishizaki | 酸化ストレス誘導細胞死の抑制剤 |
| EP2754448A3 (en) | 2007-02-09 | 2014-12-24 | Blanchette Rockefeller Neurosciences, Institute | Therapeutic effects of bryostatins, bryologs, and other related substances on head trauma-induced memory impairment and brain injury |
| US20100209914A1 (en) | 2007-05-25 | 2010-08-19 | Ore Pharmaceuticals , Inc. | Methods, systems, and kits for evaluating multiple sclerosis |
| AU2009310374B2 (en) * | 2008-03-03 | 2014-06-19 | Rxbio, Inc. | LPA receptor agonists and antagonists |
| ES2683021T3 (es) | 2008-07-28 | 2018-09-24 | Blanchette Rockefeller Neurosciences Institute | Compuestos activadores de la PKC para el tratamiento de enfermedades neurodegenerativas |
-
2009
- 2009-07-28 ES ES09790874.3T patent/ES2683021T3/es active Active
- 2009-07-28 EP EP19189948.3A patent/EP3586839A1/en not_active Withdrawn
- 2009-07-28 US US12/510,681 patent/US8163800B2/en active Active
- 2009-07-28 JP JP2011521235A patent/JP5653917B2/ja not_active Expired - Fee Related
- 2009-07-28 EP EP18172435.2A patent/EP3403650A3/en not_active Withdrawn
- 2009-07-28 CA CA2941035A patent/CA2941035A1/en not_active Abandoned
- 2009-07-28 EP EP09790874.3A patent/EP2328572B1/en not_active Not-in-force
- 2009-07-28 WO PCT/US2009/051927 patent/WO2010014585A1/en not_active Ceased
- 2009-07-28 CA CA2731171A patent/CA2731171C/en not_active Expired - Fee Related
-
2012
- 2012-02-21 US US13/401,459 patent/US9119825B2/en active Active
-
2014
- 2014-09-08 JP JP2014182597A patent/JP2015042643A/ja active Pending
-
2015
- 2015-07-20 US US14/803,762 patent/US10323011B2/en active Active
-
2016
- 2016-03-15 JP JP2016051212A patent/JP6449186B2/ja not_active Expired - Fee Related
-
2018
- 2018-06-12 JP JP2018111869A patent/JP2018168170A/ja active Pending
-
2019
- 2019-05-01 US US16/400,132 patent/US10696644B2/en active Active
-
2020
- 2020-06-17 US US16/903,551 patent/US11390596B2/en active Active
-
2022
- 2022-07-06 US US17/858,204 patent/US11820745B2/en active Active
-
2023
- 2023-10-02 US US18/375,745 patent/US20240025870A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018168170A5 (enExample) | ||
| JP2011529503A5 (enExample) | ||
| Darwesh et al. | Insights into the cardioprotective properties of n-3 PUFAs against ischemic heart disease via modulation of the innate immune system | |
| JP2020500193A5 (enExample) | ||
| Corminboeuf et al. | FPR2/ALXR agonists and the resolution of inflammation | |
| JP2014512351A5 (enExample) | ||
| CL2021000645A1 (es) | Métodos para reducir el riesgo de eventos cardiovasculares en un sujeto. | |
| PH12021550328A1 (en) | Methods of reducing the need for peripheral arterial revascularization in a statin-treated subject | |
| Lee | Resolvins as new fascinating drug candidates for inflammatory diseases | |
| A Farooqui | n-3 fatty acid-derived lipid mediators in the brain: new weapons against oxidative stress and inflammation | |
| Auvin | Fatty acid oxidation and epilepsy | |
| JP2016538254A5 (enExample) | ||
| Morin et al. | MAG‐EPA resolves lung inflammation in an allergic model of asthma | |
| NZ744990A (en) | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity | |
| JP2017526623A5 (enExample) | ||
| JP2013538817A5 (enExample) | ||
| RU2019110681A (ru) | Фармацевтическая композиция | |
| UA111967C2 (uk) | Оздоровчий харчовий продукт, що містить етилові естери жирних кислот з лляної олії, і спосіб його одержання | |
| JP2016501248A5 (enExample) | ||
| JP2016501249A5 (enExample) | ||
| Tanaka et al. | Metabolic conversion of C20 polymethylene-interrupted polyunsaturated fatty acids to essential fatty acids | |
| Moriyama et al. | Qualitative and quantitative effects of fatty acids involved in heart diseases | |
| Rashid et al. | Role of polyunsaturated fatty acids and their metabolites on stem cell proliferation and differentiation | |
| JP2012513380A5 (enExample) | ||
| Das | Telomere length and polyunsaturated fatty acids |